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ORIGINAL RESEARCH
Association Between ECG Abnormalities 
and Fatal Cardiovascular Disease Among 
Patients With and Without Severe Mental 
Illness
Christoffer Polcwiartek , MD; Brett D. Atwater , MD; Kristian Kragholm, MD, PhD; Daniel J. Friedman , MD; 
Carlo A. Barcella , MD, PhD; Rubina Attar , MD; Claus Graff , MSc, PhD; Jonas B. Nielsen , MD, PhD; 
Adrian Pietersen, MD; Peter Søgaard , MD, DMSc; Christian Torp-Pedersen, MD, DMSc;  
Svend E. Jensen , MD, PhD
BACKGROUND: ECG abnormalities are associated with adverse outcomes in the general population, but their prognostic sig-
nificance in severe mental illness (SMI) remains unexplored. We investigated associations between no, minor, and major ECG 
abnormalities and fatal cardiovascular disease (CVD) among patients with SMI compared with controls without mental illness.
METHODS AND RESULTS: We cross-linked data from Danish nationwide registries and included primary care patients with digital 
ECGs from 2001 to 2015. Patients had SMI if they were diagnosed with schizophrenia, bipolar disorder, or severe depression 
before ECG recording. Controls were required to be without any prior mental illness or psychotropic medication use. Fatal 
CVD was assessed using hazard ratios (HRs) with 95% CIs and standardized 10-year absolute risks. Of 346 552 patients, 
10 028 had SMI (3%; median age, 54 years; male, 45%), and 336 524 were controls (97%; median age, 56 years; male, 48%). 
We observed an interaction between SMI and ECG abnormalities on fatal CVD (P<0.001). Severe mental illness was associ-
ated with fatal CVD across no (HR, 2.17; 95% CI, 1.95–2.43), minor (HR, 1.90; 95% CI, 1.49–2.42), and major (HR, 1.40; 95% 
CI, 1.26–1.55) ECG abnormalities compared with controls. Across age- and sex-specific subgroups, SMI patients with ECG 
abnormalities but no CVD at baseline had highest standardized 10-year absolute risks of fatal CVD.
CONCLUSIONS: ECG abnormalities conferred a poorer prognosis among patients with SMI compared with controls without 
mental illness. SMI patients with ECG abnormalities but no CVD represent a high-risk population that may benefit from greater 
surveillance and risk management.
Key Words: ECG ■ primary care ■ risk prediction ■ severe mental illness
Patients with severe mental illness (SMI) compris-ing schizophrenia, bipolar disorder, and severe depression have excess cardiovascular risk and 
a reduced life expectancy of ≈20 years compared with 
the general population.1–3 The mortality risk of cardio-
vascular disease (CVD), such as myocardial infarc-
tion, is 30% to 40% among these patients compared 
with 10% to 15% in the general population.4 Although 
several reasons may explain differences in outcomes, 
patients with SMI are overall less likely to receive timely 
and proper medical care, including invasive coronary 
management, and tend to neglect cardiovascular 
symptoms such as chest pain, palpitations, or presyn-
cope.5,6 Therefore, there is a significant interest in early 
detection of subclinical CVD and its outcomes among 
patients with SMI.
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The ECG remains a readily available and inexpen-
sive tool to assess cardiovascular risk and preexisting 
CVD. Although prior studies have demonstrated that 
commonly encountered ECG abnormalities predict 
adverse outcomes in the general population,7–12 there 
are no published data on the prognostic significance of 
ECG abnormalities among patients with SMI. Recent 
work from our group suggests that these patients 
more often demonstrate elevated heart rate, corrected 
QT prolongation, and Q waves as a sign of prior myo-
cardial infarction, and less left ventricular hypertrophy 
and atrial fibrillation/flutter on ECGs compared with 
background population controls.13
Therefore, using a large contemporary clinical 
laboratory database including nearly 1 million digital 
ECGs cross-linked with Danish nationwide admin-
istrative registries, we investigated the association 
between ECG abnormalities and fatal CVD among 
patients with SMI compared with controls without 
any prior mental illness or psychotropic medication 
use. Considering the higher prevalence of CVD and 
overrepresentation of certain ECG abnormalities 
among patients with SMI, we hypothesized that risk 
prediction incorporating the ECG may be useful in 
this vulnerable population.
METHODS
Data were obtained from Danish nationwide adminis-
trative registries, which were available on a Statistics 
Denmark server through remote access. The authors 
declare that all supporting data are available within the 
article and its online supplementary files.
Study Design and Population
This was a registry-based retrospective cohort 
study including patients with their latest available 
digital ECG recorded between January 1, 2001, and 
December 31, 2015, at the Copenhagen General 
Practitioners’ Laboratory in Denmark. The index date 
was the day of ECG recording. The central core fa-
cility serviced primary care and specialty outpatient 
clinics including psychiatry, with various clinical ex-
aminations such as ECG recordings, as described 
previously.14
Patients were excluded in case of missing data 
on age or sex or if they were <16 years of age at the 
index date based on data obtained from the Danish 
Civil Registration System.15 Data on vital status were 
obtained from the Danish Registry of Causes of 
Death.16
SMI Definition
We used the Danish Psychiatric Central Research 
Registry17 to identify inpatient or outpatient encoun-
ters for schizophrenia (International Classification of 
Diseases, Tenth Revision [ICD-10] code: F20), bipolar 
disorder (ICD-10 codes: F30–31), or severe depression 
(ICD-10 codes: F32.2–.3 and F33.2–.3). If patients had 
more than one registered SMI diagnosis prior to the 
index date, patients were assigned to the lowest hier-
archical diagnosis code regardless of the date of onset 
to comply with the diagnostic hierarchical order of the 
ICD-10 system.
Patients were assigned as controls if they were 
without any prior mental illness (ICD-10 code: F*) 
and had not filled any prescriptions for psychotropic 
medications within 180 days prior to the index date, 
which was identified using Anatomical Therapeutic 
Chemical codes in the Danish National Prescription 
Registry.18
ECG Abnormalities
All standard 12-lead ECGs were digitally recorded at 
rest and in the supine position, stored in the MUSE 
Cardiology Information System (GE Healthcare, 
Milwaukee, WI, USA), and processed using the 
Marquette 12SL algorithm version 23.19 All ECGs 
have been over read by a consultant cardiologist. 
Using 12SL algorithm statements, we excluded ECGs 
of poor quality, ECGs with paced rhythms, or ECGs 
CLINICAL PERSPECTIVE
What Is New?
• Both minor (eg, QT prolongation) and major 
(eg, Q waves) ECG abnormalities conferred a 
poorer prognosis among patients with severe 
mental illness compared with controls without 
any prior mental illness or psychotropic medi-
cation use.
• Patients with severe mental illness and ECG 
abnormalities but no cardiovascular disease at 
baseline had a higher 10-year absolute risk of 
fatal cardiovascular disease relative to if the pa-
tient did not have either ECG abnormalities or 
severe mental illness.
What Are the Clinical Implications?
• Patients with severe mental illness have excess 
cardiovascular morbidity and mortality.
• Early detection of ECG abnormalities may offer 
a simple way to identify patients with severe 
mental illness at greater cardiovascular risk.
Nonstandard Abbreviations and Acronyms
SMI severe mental illnessDow
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unsuitable for further interpretation, as described 
previously.13
We reported data on continuous ECG measure-
ments and defined corrected QT prolongation as 
>450 ms for males and >470 ms for females using 
the Fridericia formula.20 Furthermore, ECG abnor-
malities were divided into minor (ie, first-degree 
atrioventricular, incomplete bundle branch, and left 
fascicular blocks or corrected QT prolongation) and 
major (ie, left ventricular hypertrophy, atrial fibril-
lation/flutter, bundle branch block, intraventricular 
conduction disturbance, Q waves, or ST-T devia-
tions), in accordance with contemporary studies.7,9 
Moreover, we analyzed the heart rate based on cut 
offs of <60 and >90 beats per minute. When analyz-
ing the association between ECG abnormalities and 
outcomes, patients with both minor and major ECG 
abnormalities were assigned as having major ECG 
abnormalities. Patients without any ECG abnormali-
ties were considered to have no ECG abnormalities. 
See Table S1 for an overview of criteria used to de-
fine ECG abnormalities.
Covariates
We used the Danish National Patient Registry21 to 
additionally exclude patients with a prior pacemaker 
or implantable cardioverter-defibrillator implantation 
based on either ICD-10 or Nordic Medico-Statistical 
Committee Classification of Surgical Procedures 
codes, whichever came first. The Danish National 
Patient Registry was also used to identify prior di-
agnoses of heart failure, coronary artery disease in-
cluding prior myocardial infarction, atrial fibrillation/
flutter, valvular heart disease, hypertension, hyper-
lipidemia, diabetes mellitus, chronic obstructive pul-
monary disease, and chronic kidney disease. Using 
Nordic Medico-Statistical Committee Classification 
of Surgical Procedures codes, we also identified per-
cutaneous coronary intervention or coronary artery 
bypass grafting for coronary artery disease, ablation 
for atrial fibrillation/flutter, aortic or mitral valve sur-
gery for valvular heart disease, and renal replace-
ment therapy for chronic kidney disease. We further 
identified filled prescriptions for cardiovascular medi-
cations within 180  days prior to the index date 
based on Anatomical Therapeutic Chemical codes. 
Because hypertension, hyperlipidemia, diabetes 
mellitus, and chronic obstructive pulmonary disease 
are often managed in primary care, patients may not 
necessarily have ICD codes registered. Accordingly, 
prior filled prescriptions for antihypertensives (at least 
dual therapy), lipid-lowering medications, antidiabet-
ics, and β-adrenergic or anticholinergic inhalants 
were also used to define these conditions. Finally, 
we used CredibleMeds, an internet-based registry 
of QT-prolonging medications, to identify medica-
tions associated with known or possible QT prolon-
gation risk.22 See Tables S2 and S3 for an overview 
of used ICD, Nordic Medico-Statistical Committee 
Classification of Surgical Procedures, and Anatomical 
Therapeutic Chemical codes.
Outcomes
Patients were followed from the index date until the 
occurrence of an outcome or censoring in case of 
emigration or end of study on December 31, 2017, 
whichever came first. The primary outcome fatal CVD 
was defined as death from any CVD (ICD-10 code: I*). 
We also performed an additional analysis using all-
cause mortality as a secondary outcome.
Statistical Analysis
Continuous variables were reported as medians with 
25th to 75th percentiles and categorical variables as 
counts with percentages. Between-group differences 
were compared using Mann-Whitney U and χ2 tests, 
as appropriate.
Outcomes were compared between patients 
with SMI and controls without mental illness, which 
served as the reference group, across similar lev-
els of ECG abnormalities. Cumulative incidence 
curves of fatal CVD were generated using the Aalen-
Johansen method, with death from other causes 
being accounted for as a competing risk event, and 
event distributions were compared using Gray’s 
test. Multivariable Cox regression analysis was 
used to compute hazard ratios (HRs) with 95% CIs. 
Furthermore, we performed an additional analysis 
using a dummy variable that combined SMI status 
with ECG abnormalities, in which controls without 
mental illness demonstrating no ECG abnormalities 
served as the reference. We also performed stratified 
analyses of subtype of SMI diagnosis and individual 
ECG abnormalities.
All models were adjusted for age, sex, heart fail-
ure, coronary artery disease, atrial fibrillation/flutter, 
valvular heart disease, hypertension, hyperlipidemia, 
diabetes mellitus, chronic obstructive pulmonary dis-
ease, chronic kidney disease, and QT-prolonging 
medications.
Due to nonlinearity, age was grouped by quartiles. The 
proportional hazards assumption was assessed using 
Martingale residuals and was not violated. Interaction 
testing was based on introducing an interaction term in a 
Cox regression model and using a likelihood ratio test to 
compare this model with another without an interaction 
term. Specifically, we tested for an interaction between 
SMI and ECG abnormalities on outcomes.
The time-dependent area under the receiver op-
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assess the added discriminative value of ECG abnor-
malities to a conventional risk model for the purpose of 
10-year risk prediction of fatal CVD.23 The conventional 
risk model was based on age, sex, hypertension, hy-
perlipidemia, diabetes mellitus, and chronic obstruc-
tive pulmonary disease. Patients with SMI and controls 
without mental illness were stratified by the absence/
presence of CVD at baseline, and data were split into 
training (63%) and test (37%) sets using bootstrap 
cross-validation with 1000 bootstrap samples. Brier 
scores were calculated to evaluate model calibration.24 
Furthermore, we calculated the standardized 10-year 
absolute risk of fatal CVD.24
Data management and analysis were performed 
using SAS version 9.4 (SAS Institute, Cary, NC, USA) 
and R version 3.6.1 (R Foundation for Statistical 
Computing, Vienna, Austria). A P<0.05 was considered 
statistically significant for all analyses except for during 
interaction testing where an a prior decision was made 
to use P<0.01 to account for multiple testing.
Ethics
In Denmark, registry-based studies do not require ethi-
cal committee approval or individual patient consent 
if the study is conducted for the sole purpose of sta-
tistics and scientific research, as defined in the Data 
Protection Act. Approval to use the data sources for re-
search purposes was granted by the institute respon-
sible for the data in the Capital Region of Denmark 
in accordance with the General Data Protection 
Regulation (approval number: P-2019-533).
RESULTS
Patients and Characteristics
A total of 346 552 patients with digital ECGs were in-
cluded, of whom 10 028 (3%) had SMI, and 336 524 
(97%) were controls without mental illness. See 
Figure S1 for the flowchart. Patient characteristics are 
shown in Table 1. The majority of patients with SMI had 
a diagnosis of schizophrenia (45%). The median age 
at the time of ECG recording was 54 years (25th–75th 
percentiles, 42–66 years) among patients with SMI and 
56 years (25th–75th percentiles, 41–69 years) among 
controls without mental illness. Approximately 45% 
and 48% of patients with SMI and controls without 
mental illness were male, respectively. Overall, patients 
with SMI had a higher cardiovascular comorbidity bur-
den and were less likely to fill prescriptions for cardio-
vascular medications compared with controls without 
mental illness. Furthermore, 68% of patients with SMI 
filled prescriptions for QT-prolonging medications, 
Table 1. Baseline Characteristics
Patients With SMI Controls Without Mental Illness P Value
n 10 028 336 524 NA
Age at ECG recording, y 54 [42–66] 56 [41–69] <0.001
Male 4464 (44.5) 161 282 (47.9) <0.001
Subtype of SMI diagnosis NA NA
Schizophrenia 4477 (44.6)
Bipolar disorder 2571 (25.6)
Severe depression 2980 (29.7)
SMI duration, y 8 [3–13] NA NA
Heart failure 421 (4.2) 10 433 (3.1) <0.001
Coronary artery disease 888 (8.9) 29 232 (8.7) 0.567
Atrial fibrillation/flutter 424 (4.2) 14 903 (4.4) 0.349
Valvular heart disease 123 (1.2) 3690 (1.1) 0.237
Hypertension 1479 (14.7) 50 432 (15.0) 0.521
Hyperlipidemia 1686 (16.8) 49 201 (14.6) <0.001
Diabetes mellitus 1222 (12.2) 26 732 (7.9) <0.001
Chronic obstructive pulmonary disease 1351 (13.5) 29 093 (8.6) <0.001
Chronic kidney disease 311 (3.1) 6328 (1.9) <0.001
ACEIs/ARBs 1401 (14.0) 64 743 (19.2) <0.001
Beta-blockers 765 (7.6) 32 384 (9.6) <0.001
Diuretics 1467 (14.6) 45 533 (13.5) 0.002
QT-prolonging medications 6819 (68.0) 44 377 (13.2) <0.001
Data are reported as median (25th–75th percentiles) or n (%). P values based on Mann-Whitney U and χ2 tests, as appropriate. ACEI indicates angiotensin-
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which in most cases were antipsychotics or antide-
pressants (61%).
ECG characteristics are shown in Table 2. The dis-
tribution of ECG abnormalities was overall similar be-
tween patients with SMI (no, 73%; minor, 7%; major, 
21%) and controls without mental illness (no, 71%; 
minor, 6%; major, 24%).
See Tables S4 and S5 for patient and ECG charac-
teristics stratified by subtype of SMI diagnosis.
Associations Between SMI, ECG 
Abnormalities, and Adverse Outcomes
During a median follow-up of 6 years (25th–75th per-
centiles, 3–10 years), 23% of patients with SMI and 
17% of controls without mental illness died, with fatal 
CVD accounting for 10% among patients with SMI and 
8% among controls without mental illness. Across all 
levels of ECG abnormalities, patients with SMI had the 
highest rate of fatal CVD (P<0.001) (Figure 1).
We observed an interaction between SMI and ECG 
abnormalities on fatal CVD (P<0.001) as well as all-cause 
mortality (P<0.001). Severe mental illness was associated 
with fatal CVD across no (HR, 2.17; 95% CI, 1.95–2.43), 
minor (HR, 1.90; 95% CI, 1.49–2.42), and major (HR, 
1.40; 95% CI, 1.26–1.55) ECG abnormalities compared 
with controls without mental illness (Figure 2A). Overall, 
similar results were observed with all-cause mortality 
(Figure  2B). Furthermore, when using a dummy vari-
able that combined SMI status and ECG abnormalities, 
Table 2. ECG Characteristics
Patients With SMI 
Controls Without Mental 
Illness  P Value
n 10 028 336 524 NA
Heart rate, bpm 75 [66–86] 69 [61–78] <0.001
Missing 686 30 361
P-wave duration, ms 108 [100–116] 108 [100–116] <0.001
Missing 686 30 361
PR interval, ms 156 [142–172] 156 [144–174] 0.604
Missing 686 30 361
QRS duration, ms 90 [84–98] 92 [84–100] <0.001
Missing 686 30 361
QT interval, ms 388 [366–410] 396 [376–416] <0.001
Missing 686 30 361
QTcF interval, ms 417 [404–431] 414 [402–427] <0.001
Missing 686 30 361
No ECG abnormality 7295 (72.7) 237 397 (70.5) <0.001
Minor ECG abnormality 660 (6.6) 18 541 (5.5) <0.001
First-degree atrioventricular block 384 (3.8) 13 477 (4.0) 0.391
Incomplete bundle branch block 210 (2.1) 8504 (2.5) 0.007
Incomplete right bundle branch block 192 (1.9) 7680 (2.3) 0.016
Incomplete left bundle branch block 18 (0.2) 824 (0.2) 0.227
Left fascicular block 177 (1.8) 4504 (1.3) <0.001
Left anterior fascicular block 102 (1.0) 2743 (0.8) 0.031
Left posterior fascicular block 75 (0.7) 1761 (0.5) 0.003
QTcF prolongation 324 (3.2) 5831 (1.7) <0.001
Major ECG abnormality 2073 (20.7) 80 586 (23.9) <0.001
Left ventricular hypertrophy 850 (8.5) 35 832 (10.6) <0.001
Atrial fibrillation/flutter 234 (2.3) 12 561 (3.7) <0.001
Bundle branch block 302 (3.0) 11 550 (3.4) 0.024
Right bundle branch block 217 (2.2) 7803 (2.3) 0.326
Left bundle branch block 85 (0.8) 3747 (1.1) 0.014
Intraventricular conduction disturbance 76 (0.8) 2786 (0.8) 0.479
Q waves 541 (5.4) 17 064 (5.1) 0.152
ST-T deviations 381 (3.8) 15 283 (4.5) <0.001
Data are reported as median (25th–75th percentiles) or n (%). P values based on Mann-Whitney U and χ2 tests, as appropriate. bpm indicates beats per 
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fatal CVD rate was increased among patients with 
SMI demonstrating no (HR, 2.11; 95% CI, 1.89–2.35), 
minor (HR, 2.78; 95% CI, 2.22–3.48), or major (HR, 
3.23; 95% CI, 2.91–3.58) ECG abnormalities compared 
with controls without mental illness demonstrating no 
ECG abnormalities. Similar but less pronounced rates 
were observed among controls without mental illness 
demonstrating minor (HR, 1.37; 95% CI, 1.30–1.45) or 
major (HR, 2.26; 95% CI, 2.20–2.33) ECG abnormalities 
(Figure S2A). As in the main analysis, similar results were 
obtained with all-cause mortality (Figure S2B).
When stratifying by subtype of SMI diagnosis, the 
interaction was driven by schizophrenia (P<0.001) 
rather than bipolar disorder (P=0.628) or severe de-
pression (P=0.150), and patients with schizophrenia 
also had the worst prognosis (Figure S3).
Most of the individual minor and major ECG ab-
normalities as well as heart rate <60 or >90 beats 
per minute conferred a poorer prognosis among 
patients with SMI compared with controls without 
mental illness (Figure 3). In particular, an increased 
rate of fatal CVD was associated with patients with 
SMI demonstrating incomplete bundle branch block 
(HR, 2.29; 95% CI, 1.47–3.56), intraventricular con-
duction disturbance (HR, 2.00; 95% CI, 1.15–3.47), 
heart rate <60 beats per minute (HR, 1.64; 95% CI, 
1.20–2.24), Q waves (HR, 1.57; 95% CI, 1.28–1.94), 
or heart rate >90 beats per minute (HR, 1.50; 95% 
CI, 1.25–1.79).
10-Year Risk Prediction
Adding ECG abnormalities to a conventional risk 
model increased the AUC for the 10-year risk predic-
tion of fatal CVD only among the subset of patients 
with SMI without CVD at baseline (difference in AUC, 
2.33%; 95% CI, 0.17%–4.18%). No model improvement 
was observed among the subset of patients with SMI 
and CVD at baseline. Contrarily, model improvement 
was observed among controls without mental illness 
regardless of baseline CVD status. See Figure S4 and 
Table S6 for AUC results including Brier scores.
As model improvement with ECG abnormalities 
was most pronounced in the non-CVD population, 
we calculated the standardized 10-year absolute risk 
of fatal CVD for levels of ECG abnormalities strati-
fied by age groups, sex, and SMI status, as shown in 
Figure 4. Patterns of increasing risk with minor and 
major ECG abnormalities were observed among pa-
tients with SMI.
Figure 1. Cumulative incidence curves of fatal CVD among patients with SMI and controls without mental illness across no 
(A), minor (B), and major (C) ECG abnormalities.






 http://ahajournals.org by on June 1, 2021
J Am Heart Assoc. 2021;10:e019416. DOI: 10.1161/JAHA.120.019416 7
Polcwiartek et al ECG Abnormalities and Fatal CVD in SMI
DISCUSSION
In this large-scale study, we report several key find-
ings underscoring a differential association between 
ECG abnormalities and adverse outcomes among 
primary care patients with SMI compared with con-
trols without mental illness. First, patients with SMI 
demonstrating minor or major ECG abnormalities had 
a poorer prognosis compared with the control group. 
Second, we observed clinically relevant differences 
in fatal CVD associated with individual ECG abnor-
malities among patients with SMI, where particularly 
incomplete bundle branch block, intraventricular 
conduction disturbance, and Q waves conferred a 
poorer prognosis. Finally, among patients with SMI 
but no CVD at baseline, adding ECG abnormalities 
to a conventional risk model improved 10-year risk 
prediction of fatal CVD.
Several prior studies have reported associations be-
tween minor and major ECG abnormalities and adverse 
outcomes,7–12 and the magnitude of risk associated with 
abnormal ECGs varied across different populations. 
This is emphasized in clinical guideline recommenda-
tions for the utilization of the ECG as a screening tool 
among asymptomatic adults.25,26 However, considering 
that the distribution of ECG abnormalities varies among 
Figure 2. Multivariable Cox regression of the association between SMI and fatal CVD (A) and all-cause mortality (B) across 
no, minor, and major ECG abnormalities.
Adjusted for age, sex, heart failure, coronary artery disease, atrial fibrillation/flutter, valvular heart disease, hypertension, hyperlipidemia, 
diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, and QT-prolonging medications. CVD indicates 
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patients with SMI compared with a psychiatrically 
healthy population,13 and that no studies have investi-
gated their prognostic significance, evidence to sug-
gest clear clinical ECG recommendations in the setting 
of SMI is lacking. This underscores the importance of 
our comprehensive study and adds to the evidence of 
the potential benefit of the ECG as a cardiovascular risk 
stratification tool among patients with SMI. However, the 
optimal frequency and cost-effectiveness of using the 
ECG to screen for CVD during routine clinical care of 
patients with SMI need to be explored.
Our finding of an association between ECG ab-
normalities and adverse outcomes that was particu-
larly important among patients with SMI, as identified 
by interaction testing, has been underrecognized and 
not previously described. Moreover, considering the 
excess cardiovascular morbidity and mortality as well 
as poor cardiovascular care across other mental ill-
nesses and patients treated with psychotropic med-
ications only,27 ECG abnormalities may also prove 
valuable in assessing cardiovascular risk among these 
patients. However, further studies are warranted to 
explore this. Although several common major ECG 
abnormalities conferred a poorer prognosis among 
patients with SMI in our study, clinicians should also 
pay attention to those who are demonstrating minor 
ECG abnormalities, as they are at high cardiovascular 
risk. Overall, this suggests that CVD may have a more 
severe course in the setting of SMI, which may be due 
to a multifactorial interplay of genetic risk, immune sys-
tem alterations, unhealthy lifestyle, adverse effects of 
psychotropic medications, lack and neglect of timely 
cardiovascular care, cognitive impairment, and social 
deprivation.1,28 Furthermore, a majority of patients with 
SMI experience sudden cardiac death as the first man-
ifestation of CVD.29 In most cases, this may be due to 
undetected or silent myocardial infarction, as identified 
by Q waves on the ECG, which occurs in up to 75% of 
patients with schizophrenia.30 In our recent work, we 
observed an overrepresentation of Q waves among pa-
tients with SMI compared with a psychiatrically healthy 
population,13 and the current study demonstrated that 
Q waves are not only more prevalent but also associ-
ated with an increase in mortality over time (HR of 1.57).
Contemporary risk prediction algorithms for CVD 
have been shown to underestimate the risk among pa-
tients with SMI.31 Accordingly, to assess if ECG abnor-
malities improved risk prediction on an individual level 
compared with a conventional risk model, we calcu-
lated measures of discrimination of 10-year risk of fatal 
CVD and observed improvement with ECG abnormal-
ities in the AUC by ≈2% points among patients with 
Figure 3. Multivariable Cox regression of the association between individual ECG abnormalities and fatal CVD for patients 
with SMI compared with controls without mental illness.
Adjusted for age, sex, heart failure, coronary artery disease, atrial fibrillation/flutter, valvular heart disease, hypertension, hyperlipidemia, 
diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, and QT-prolonging medications. bpm indicates 
beats per minute; CVD, cardiovascular disease; HR, hazard ratio; QTc, corrected QT; and SMI, severe mental illness.D
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SMI but no CVD at baseline. Furthermore, ECG ab-
normalities conferred very high standardized 10-year 
absolute risks of fatal CVD. For example, we predicted 
a 55-year-old female with SMI but no CVD at baseline 
who demonstrated a minor ECG abnormality to have a 
19% 10-year absolute risk of fatal CVD compared with 
4% if she had no ECG abnormality or 1% if she had no 
SMI. Based on our findings, we suggest that primary 
care patients with SMI, not already treated for or diag-
nosed with CVD, merit close monitoring and follow-up, 
and clinicians should incorporate a multidisciplinary 
approach to caring for patients with SMI and newly de-
tected ECG abnormalities.
Limitations
Our study has several limitations. Both unmeasured 
and unknown confounding including cardiovascular 
symptoms, cardiovascular family history, and lifestyle 
factors including smoking may affect findings, but such 
data were not available in our registries. However, we 
indirectly accounted for smoking by adjusting analyses 
for a diagnosis of chronic obstructive pulmonary dis-
ease or filled prescriptions for inhalants. Furthermore, 
the use of large sample sizes may reduce variation in 
data, and by performing several between-group com-
parisons, statistically significant differences that are not 
necessarily clinically meaningful may appear. In par-
ticular, this was the case with most of the continuous 
ECG measurements. Although most patients with SMI 
undergo routine ECG examinations in primary care, 
particularly for screening for corrected QT prolonga-
tion, data on ECG indications were unfortunately not 
available. However, the proportional hazards assump-
tion was not violated, indicating that the observed as-
sociations were not driven by accumulation of events 
in close proximity to the ECG recording. Finally, fatal 
CVD was used as our primary outcome, but the num-
ber of medicolegal autopsies has decreased over re-
cent years in Denmark. Therefore, in some cases, the 
cause of death was based on a subjective judgement 
by clinicians, and caution should be taken when inter-
preting data. Therefore, we used all-cause mortality as 
a secondary outcome, which for no ECG abnormalities 
showed a comparable rate (HR of 2.30) to fatal CVD 
(HR of 2.17), suggesting that although patients with 
SMI do not have established risk factors or recognized 
CVD, they still have excess cardiovascular mortality. 
For minor and major ECG abnormalities, we observed 
increased rates of all-cause mortality compared with 
fatal CVD, suggesting that patients with ECG abnor-
malities may be more comorbid than if they had a nor-
mal ECG and thus have an overall poorer prognosis.
CONCLUSIONS
In a large contemporary primary care population, ECG 
abnormalities conferred a poorer prognosis among pa-
tients with SMI compared with controls without men-
tal illness. SMI patients with ECG abnormalities but no 
Figure 4. Risk chart showing the standardized 10-year absolute risk of fatal CVD 
among patients with SMI and controls without mental illness free of CVD at baseline 
across ECG abnormalities and age- and sex-specific subgroups.
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CVD at baseline represent a high-risk population that 
may benefit from greater surveillance and cardiovas-
cular risk management.
ARTICLE INFORMATION
Received September 15, 2020; accepted December 9, 2020.
Affiliations
From the Department of Cardiology, Aalborg University Hospital, Aalborg, 
Denmark (C.P., K.K., R.A., P.S., C.T.-P., S.E.J.); Division of Cardiology, 
Duke University Medical Center, Durham, NC (C.P., B.D.A.); Department 
of Clinical Medicine, Aalborg University, Aalborg, Denmark (C.P., P.S., 
S.E.J.); Section of Cardiac Electrophysiology, Yale School of Medicine, 
New Haven, CT (D.J.F.); Department of Cardiology, Copenhagen University 
Hospital Gentofte, Hellerup, Denmark (C.A.B.); Department of Clinical 
Sciences, Lund University, Lund, Sweden (R.A.); Department of Health 
Science and Technology, Aalborg University, Aalborg, Denmark (C.G.); 
Laboratory for Molecular Cardiology, The Heart Center, Copenhagen 
University Hospital, Rigshospitalet, Copenhagen, Denmark (J.B.N.); 
Copenhagen General Practitioners’ Laboratory, Copenhagen, Denmark 
(A.P.); and Department of Cardiology and Clinical Research, Nordsjælland 
Hospital, Hillerød, Denmark (C.T.-P.).
Sources of Funding
This study was supported by Departmental Sources, the Danish Heart 
Foundation (grant number: 18-R125-A8382-22086), Eva and Henry Frænkel 
Memorial Foundation, and Overlæge dr. med. Einar Geert-Jørgensen 
og Hustrus Forskningslegat. The funding sources had no influence on 
study design; collection, analysis, or interpretation of data; writing of the 
manuscript; or decision to submit the manuscript for publication.
Disclosures
Dr Polcwiartek reported receiving speaking fees from Lundbeck Pharma 
A/S. Dr Atwater reported receiving speaking fees from Medtronic; re-
search grants from Abbott and Boston Scientific; and acting as adviser to 
Abbott, Biotronik, and Medtronic. Dr Kragholm reported receiving speaking 
fees from Novartis and a research grant from the Laerdal Foundation. Dr 
Friedman reported receiving salary support from the National Institutes of 
Health; research grants from Abbott, Biosense Webster, Boston Scientific, 
and the National Cardiovascular Data Registry; and educational grants from 
Abbott, Biotronik, Boston Scientific, and Medtronic. Dr Søgaard reported re-
ceiving research grants from Biotronik and GE Healthcare and acting as ad-
viser to Biotronik. Dr Torp-Pedersen reported receiving speaking fees from 
Bayer and research grants from Bayer and Biotronik. Dr Jensen reported 
receiving a research grant from the Obel Family Foundation. The remaining 






 1. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients 
with severe mental illness. Nat Rev Cardiol. 2020 Oct 30 [epub ahead of 
print]. DOI: 10.1038/s4156 9-020-00463 -7
 2. Lomholt LH, Andersen DV, Sejrsgaard-Jacobsen C, Øzdemir CM, Graff 
C, Schjerning O, Jensen SE, Straszek SPV, Licht RW, Grøntved S, et al. 
Mortality rate trends in patients diagnosed with schizophrenia or bipo-
lar disorder: a nationwide study with 20 years of follow-up. Int J Bipolar 
Disord. 2019;7:6.
 3. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, 
Santonastaso P, Thapa-Chhetri N, Fornaro M, Gallicchio D, 
Collantoni E, et al. Prevalence, incidence and mortality from car-
diovascular disease in patients with pooled and specific severe 
mental illness: a large-scale meta-analysis of 3,211,768 patients 
and 113,383,368 controls. World Psychiatry. 2017;16:163–180. 
DOI: 10.1002/wps.20420
 4. Bodén R, Molin E, Jernberg T, Kieler H, Lindahl B, Sundström J. Higher 
mortality after myocardial infarction in patients with severe mental ill-
ness: a nationwide cohort study. J Intern Med. 2015;277:727–736. DOI: 
10.1111/joim.12329
 5. Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia 
is associated with excess multiple physical-health comorbidities but low 
levels of recorded cardiovascular disease in primary care: cross-sec-
tional study. BMJ Open. 2013;3:e002808. DOI: 10.1136/bmjop 
en-2013-002808
 6. Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Næss O, 
Ystrom E, Reichborn-Kjennerud T, Hultman CM, Nesvåg R, Høye A. 
Undiagnosed cardiovascular disease prior to cardiovascular death 
in individuals with severe mental illness. Acta Psychiatr Scand. 
2019;139:558–571. DOI: 10.1111/acps.13017
 7. Auer R, Bauer DC, Marques-Vidal P, Butler J, Min LJ, Cornuz J, 
Satterfield S, Newman AB, Vittinghoff E, Rodondi N. Association 
of major and minor ECG abnormalities with coronary heart disease 
events. JAMA. 2012;307:1497–1505. DOI: 10.1001/jama.2012.434
 8. Jørgensen PG, Jensen JS, Marott JL, Jensen GB, Appleyard M, 
Mogelvang R. Electrocardiographic changes improve risk prediction 
in asymptomatic persons age 65 years or above without cardiovas-
cular disease. J Am Coll Cardiol. 2014;64:898–906. DOI: 10.1016/j.
jacc.2014.05.050
 9. Denes P, Larson JC, Lloyd-Jones DM, Prineas RJ, Greenland P. Major 
and minor ECG abnormalities in asymptomatic women and risk of car-
diovascular events and mortality. JAMA. 2007;297:978–985. 10.1001/
jama.297.9.978
 10. Gorodeski EZ, Ishwaran H, Blackstone EH, Lauer MS. Quantitative 
electrocardiographic measures and long-term mortality in exercise test 
patients with clinically normal resting electrocardiograms. Am Heart J. 
2009;158:61–70.e1. DOI: 10.1016/j.ahj.2009.04.015
 11. Hari KJ, Singleton MJ, Ahmad MI, Soliman EZ. Relation of minor 
electrocardiographic abnormalities to cardiovascular mortality. Am J 
Cardiol. 2019;123:1443–1447. DOI: 10.1016/j.amjca rd.2019.01.050
 12. Polcwiartek C, Kragholm K, Friedman DJ, Atwater BD, Graff C, Nielsen 
JB, Holst AG, Struijk JJ, Pietersen A, Svendsen JH, et al. Long-term 
prognostic value of less-stringent electrocardiographic Q waves and 
Fourth Universal Definition of Myocardial Infarction Q waves. Am J Med. 
2020;133:582–589.e7. DOI: 10.1016/j.amjmed.2019.08.056
 13. Polcwiartek C, Kragholm K, Hansen SM, Atwater BD, Friedman 
DJ, Barcella CA, Graff C, Nielsen JB, Pietersen A, Nielsen J, et al. 
Electrocardiogram characteristics and their association with psy-
chotropic drugs among patients with schizophrenia. Schizophr Bull. 
2020;46:354–362.
 14. Nielsen JB, Graff C, Pietersen A, Lind B, Struijk JJ, Olesen MS, Haunsø 
S, Gerds TA, Svendsen JH, Køber L, et al. J-shaped association be-
tween QTc interval duration and the risk of atrial fibrillation: results from 
the Copenhagen ECG study. J Am Coll Cardiol. 2013;61:2557–2564. 
DOI: 10.1016/j.jacc.2013.03.032
 15. Pedersen CB. The Danish civil registration system. Scand J Public 
Health. 2011;39:22–25. DOI: 10.1177/14034 94810 387965
 16. Helweg-Larsen K. The Danish register of causes of death. Scand J 
Public Health. 2011;39:26–29. DOI: 10.1177/14034 94811 399958
 17. Mors O, Perto GP, Mortensen PB. The Danish psychiatric cen-
tral research register. Scand J Public Health. 2011;39:54–57. DOI: 
10.1177/14034 94810 395825
 18. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescrip-
tion registry. Scand J Public Health. 2011;39:38–41. DOI: 10.1177/14034 
94810 394717
 19. GE Healthcare. Marquette 12SL ECG analysis program physician’s 
guide. 2015. https://www.gehea lthca re.com/en-GB/produ cts/diagn 
ostic -cardi ology/ marqu ette-12sl. Accessed November 12, 2020.
 20. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and 
what is "normal". J Cardiovasc Electrophysiol. 2006;17:333–336. DOI: 
10.1111/j.1540-8167.2006.00408.x
 21. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient regis-
ter. Scand J Public Health. 2011;39:30–33. DOI: 10.1177/14034 94811 
401482
 22. CredibleMeds. Drugs that prolong QT & induce Torsades de Pointes 
(TdP). 2020. https://www.Credi bleMe ds.org/. Accessed September 01, 
2020.
 23. Blanche P, Kattan MW, Gerds TA. The c-index is not proper for the 





 http://ahajournals.org by on June 1, 2021
J Am Heart Assoc. 2021;10:e019416. DOI: 10.1161/JAHA.120.019416 11
Polcwiartek et al ECG Abnormalities and Fatal CVD in SMI
 24. Gerds TA, Scheike TH, Andersen PK. Absolute risk regression for com-
peting risks: interpretation, link functions, and prediction. Stat Med. 
2012;31:3921–3930. DOI: 10.1002/sim.5459
 25. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, 
Foster E, Hlatky MA, Hodgson JM, Kushner FG, et al. 2010 ACCF/AHA 
guideline for assessment of cardiovascular risk in asymptomatic adults: 
executive summary: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. 
Circulation. 2010;122:2748–2764. DOI: 10.1161/CIR.0b013 e3182 051bab
 26. Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson 
KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, et al. Screening 
for cardiovascular disease risk with electrocardiography: US 
Preventive Services Task Force Recommendation Statement. JAMA. 
2018;319:2308–2314. DOI: 10.1001/jama.2018.6848
 27. Barcella CA, Mohr GH, Kragholm KH, Gerds TA, Jensen SE, Polcwiartek 
C, Wissenberg M, Lippert FK, Torp-Pedersen C, Kessing LV, et al. 
Out-of-hospital cardiac arrest in patients with and without psychiatric 
disorders: differences in use of coronary angiography, coronary revas-
cularization, and implantable cardioverter-defibrillator and survival. J 
Am Heart Assoc. 2019;8:e012708. DOI: 10.1161/JAHA.119.012708
 28. Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. 
Pathophysiological mechanisms of increased cardiometabolic risk in 
people with schizophrenia and other severe mental illnesses. Lancet 
Psychiatry. 2015;2:452–464. DOI: 10.1016/S2215 -0366(15)00115 -7
 29. Koponen H, Alaräisänen A, Saari K, Pelkonen O, Huikuri H, Raatikainen 
MJ, Savolainen M, Isohanni M. Schizophrenia and sudden car-
diac death: a review. Nord J Psychiatry. 2008;62:342–345. DOI: 
10.1080/08039 48080 1959323
 30. Nielsen J, Juel J, Alzuhairi KS, Friis R, Graff C, Kanters JK, Jensen SE. 
Unrecognised myocardial infarction in patients with schizophrenia. Acta 
Neuropsychiatr. 2015;27:106–112. DOI: 10.1017/neu.2014.41
 31. Osborn DPJ, Hardoon S, Omar RZ, Holt RIG, King M, Larsen J, Marston 
L, Morris RW, Nazareth I, Walters K, et al. Cardiovascular risk prediction 
models for people with severe mental illness: results from the prediction 
and management of cardiovascular risk in people with severe mental ill-
nesses (PRIMROSE) research program. JAMA Psychiatry. 2015;72:143–
151. DOI: 10.1001/jamap sychi atry.2014.2133
 32. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, Bailey 
JJ, Childers R, Gorgels A, Josephson M, et al. AHA/ACCF/HRS recom-
mendations for the standardization and interpretation of the electrocar-
diogram: part V: electrocardiogram changes associated with cardiac 
chamber hypertrophy: a scientific statement from the American Heart 
Association Electrocardiography and Arrhythmias Committee, Council 
on Clinical Cardiology; the American College of Cardiology Foundation; 
and the Heart Rhythm Society. Endorsed by the International Society 
for Computerized Electrocardiology. Circulation. 2009;119:e251–e261. 
DOI: 10.1161/CIRCU LATIO NAHA.108.191097
 33. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and 
what is “normal”. J Cardiovasc Electrophysiol. 2006;17:333–336. DOI: 
10.1111/j.1540-8167.2006.00408.x
 34. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, 
White HD. Fourth Universal Definition of Myocardial Infarction (2018). 
Circulation. 2018;138:e618–e651.
 35. Deshpande A, Birnbaum Y. ST-segment elevation: distinguishing ST 
elevation myocardial infarction from ST elevation secondary to nonisch-
emic etiologies. World J Cardiol. 2014;6:1067–1079. DOI: 10.4330/wjc.
v6.i10.1067
 36. Rasmussen PV, Nielsen JB, Pietersen A, Graff C, Lind B, Struijk JJ, 
Olesen MS, Haunsø S, Køber L, Svendsen JH, et al. Electrocardiographic 
precordial ST-segment deviations and the risk of cardiovascular 






































 http://ahajournals.org by on June 1, 2021
 
Table S1. Overview of criteria used to define ECG abnormalities. 
ECG Abnormalities Criteria 
LVH32 
Sokolow-Lyon criteria: 
S wave in lead V1 and R wave in leads V5–V6 (largest) ≥35 mm 
Cornell voltage criteria: 
S wave in lead V3 and R wave in lead aVL >28 mm (male) or >20 mm 
(female) 
Requiring absence of: 
RBBB, LBBB, and IVCD 
Atrial fibrillation/flutter19 
Fibrillation or flutter waves with irregular or regular RR intervals, 
respectively 
First-degree AV block19 PR interval >200 ms 
RBBB19 
QRS duration >120 ms 
rSR’ pattern in leads V1–V2 
S-wave duration >R-wave duration or >40 ms in leads I and V6 
Normal R peak in leads V5–V6 but >50 ms in lead V1 
Incomplete RBBB19 
QRS duration <120 ms 
RBBB pattern 
LBBB19 
QRS duration >120 ms 
Absent Q waves in leads I and V5–V6 
R-wave peak time >60 ms in leads V5–V6 
Notched R wave in leads I, aVL, and V5–V6 
Incomplete LBBB19 
QRS duration <120 ms 
LBBB pattern 
LAFB19 
QRS duration <120 ms 
Frontal plane axis between –45 and –90 degrees 
qR pattern in lead aVL 
R-wave peak time in lead aVL >45 ms 
LPFB19 
QRS duration <120 ms 
Frontal plane axis between 90 and 180 degrees 
rS pattern in leads I and aVL 
qR pattern in leads III and aVF 
IVCD 
QRS duration >120 ms 
Requiring absence of: 
RBBB and LBBB 
QTc prolongation33 Fridericia-corrected QT interval >450 ms (male) or >470 ms (female) 
Q waves34 
Any Q wave in leads V2–V3 >20 ms or QS complex in leads V2–V3 
Q wave ≥30 ms and ≥1 mm or QS complex in leads I, II, aVL, aVF, or V4–
V6 in any two leads of a contiguous lead grouping (I, aVL; V1–V6; II, III, 
aVF) 
R wave >40 ms in leads V1–V2 and R/S >1 with a concordant positive T 
wave 
Requiring absence of: 
LVH, RBBB, LBBB, and IVCD 
ST depression or inverted 
T waves34,35 
New horizontal or downsloping ST depression ≥0.5 mm in any two leads of a 
contiguous lead grouping (I, aVL; V1–V6; II, III, aVF) 
T-wave inversion >1 mm in any two leads of a contiguous lead grouping (I, 
aVL; V1–V6; II, III, aVF) with prominent R wave or R/S ratio >1 
Requiring absence of (in leads V1–V3): 
RBBB, LBBB, and IVCD 
ST elevation34,35,36 
New ST elevation at the J point* in any two leads of a contiguous lead 
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≥1 mm in all leads other than leads V2–V3, where the following cut-off 
levels apply: 
≥2 mm in male ≥40 years 
≥2.5 mm in male <40 years 
≥1.5 mm in female regardless of age 
Requiring absence of (in leads V1–V3): 
RBBB, LBBB, IVCD 
*Criteria for ST elevation were slightly modified as measurement of the ST segment was performed at QRS 
offset + 1/16 of the average RR interval, known as the STM point in the 12SL algorithm and equivalent to ~80 
ms after QRS offset. STM was chosen instead of the J point as a notched or slurred appearance of the terminal 
QRS complex (i.e. early repolarization) can make it difficult to define the J point. 
Abbreviations: AV, atrioventricular; ECG, electrocardiogram; IVCD, intraventricular conduction disturbance; 
LVH, left ventricular hypertrophy; QTc, corrected QT; RBBB, right bundle branch block; LAFB, left anterior 
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Table S2. Overview of ICD-8, ICD-10, NCSP, and ATC codes used to identify medical comorbidities, 
procedures, and cardiovascular medications. 






Z95.0 BFCA–B  
Heart failure 
425, 427.0–.1; I11.0, I13.0, I13.2, I42, I50, 
J81 
  











Valvular heart disease 394–396, 424.0–.1; I05–06, I34–35 KFK, KFM  
Hypertension 400–404; I10–15  
C02–03, 
C07–09 
Hyperlipidemia 279.00; E78.0–.5  C10 
Diabetes 250; E10–14  A10 
Chronic obstructive 
pulmonary disease 





Chronic kidney disease 
250.02, 400.39, 403–404, 581–584, 
590.09, 593.20, 753.10–.11, 753.19; I12.0, 
N02–08, N11–14, N15.8–.9, N16, N18–19, 
N26, N39.1, M32.1B, Q61, Z99.2 
BJFD2  
Diuretics   
C03A, C03C, 
C03EB 
ACEIs/ARBs   C09A–D 
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Table S3. Overview of QT-prolonging medications. From https://www.crediblemeds.org/. Up to date as 















































































Lopinavir and ritonavir J05AR10 

























































































































Antiparasitics, insecticides, and repellents 
Chloroquine P01BA01 
Hydroxychloroquine P01BA02 
Primaquine phosphate P01BA03 
Arthemether P01BF01 
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Age at ECG recording, 
years 
56 [41–69] 50 [39–61] 58 [44–70] 58 [45–72] <0.001 
Males 161 282 (47.9) 2443 (54.6) 987 (38.4) 1034 (34.7) <0.001 
SMI duration, years NA 10 [5–16] 7 [3–12] 5 [2–9] NA 
Heart failure 10 433 (3.1) 158 (3.5) 117 (4.6) 146 (4.9) <0.001 
Coronary artery disease 29 232 (8.7) 304 (6.8) 250 (9.7) 334 (11.2) <0.001 
Atrial fibrillation/flutter 14 903 (4.4) 120 (2.7) 135 (5.3) 169 (5.7) <0.001 
Valvular heart disease 3690 (1.1) 36 (0.8) 36 (1.4) 51 (1.7) 0.001 
Hypertension 50 432 (15.0) 490 (10.9) 420 (16.3) 569 (19.1) <0.001 
Hyperlipidemia 49 201 (14.6) 689 (15.4) 462 (18.0) 535 (18.0) <0.001 
Diabetes 26 732 (7.9) 644 (14.4) 288 (11.2) 290 (9.7) <0.001 
Chronic obstructive 
pulmonary disease 
29 093 (8.6) 655 (14.6) 337 (13.1) 359 (12.0) <0.001 
Chronic kidney disease 6328 (1.9) 108 (2.4) 119 (4.6) 84 (2.8) <0.001 
ACEIs/ARBs 64 743 (19.2) 515 (11.5) 378 (14.7) 508 (17.0) <0.001 
Beta-blockers 32 384 (9.6) 290 (6.5) 200 (7.8) 275 (9.2) <0.001 
Diuretics 45 533 (13.5) 565 (12.6) 430 (16.7) 472 (15.8) <0.001 
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Heart rate, bpm 69 [61–78] 78 [68–89] 72 [64–82] 75 [66–85] <0.001 
Missing 30 361 219 228 239  
P-wave duration, ms 108 [100–116] 106 [98–114] 110 [102–118] 108 [100–116] <0.001 
Missing 30 361 219 228 239  
PR interval, ms 156 [144–174] 154 [140–168] 162 [146–178] 156 [142–172] 0.782 
Missing 30 361 219 228 239  
QRS duration, ms 92 [84–100] 90 [84–98] 92 [84–100] 90 [84–98] <0.001 
Missing 30 361 219 228 239  
QT interval, ms 396 [376–416] 384 [362–404] 394 [374–416] 390 [370–410] <0.001 
Missing 30 361 219 228 239  
QTcF interval, ms 414 [402–427] 416 [402–430] 418 [404–431] 417 [405–431] <0.001 
Missing 30 361 219 228 239  
No ECG abnormality 237 397 (70.5) 3380 (75.5) 1789 (69.6) 2126 (71.3) <0.001 
Minor ECG abnormality 18 541 (5.5) 292 (6.5) 189 (7.4) 179 (6.0) <0.001 
First-degree 
atrioventricular block 
13 477 (4.0) 107 (2.4) 144 (5.6) 133 (4.5) <0.001 
Incomplete bundle branch 
block 
8504 (2.5) 97 (2.2) 58 (2.3) 55 (1.8) 0.036 
Incomplete right bundle 
branch block 
7680 (2.3) 92 (2.1) 49 (1.9) 51 (1.7) 0.076 
Incomplete left bundle 
branch block 
824 (0.2) 5 (0.1) 9 (0.4) 4 (0.1) 0.116 
Left fascicular block 4504 (1.3) 85 (1.9) 42 (1.6) 50 (1.7) 0.002 
Left anterior fascicular 
block 
2743 (0.8) 40 (0.9) 30 (1.2) 32 (1.1) 0.088 
Left posterior fascicular 
block 
1761 (0.5) 45 (1.0) 12 (0.5) 18 (0.6) <0.001 
QTcF prolongation 5831 (1.7) 159 (3.6) 90 (3.5) 75 (2.5) <0.001 
Major ECG abnormality 80 586 (23.9) 805 (18.0) 593 (23.1) 675 (22.7) <0.001 
Left ventricular 
hypertrophy 
35 832 (10.6) 322 (7.2) 242 (9.4) 286 (9.6) <0.001 
Atrial fibrillation/flutter 12 561 (3.7) 52 (1.2) 84 (3.3) 98 (3.3) <0.001 
Bundle branch block 11 550 (3.4) 104 (2.3) 97 (3.8) 101 (3.4) <0.001 
Right bundle branch block 7803 (2.3) 77 (1.7) 69 (2.7) 71 (2.4) 0.035 
Left bundle branch block 3747 (1.1) 27 (0.6) 28 (1.1) 30 (1.0) 0.013 
Intraventricular conduction 
disturbance 
2786 (0.8) 29 (0.6) 23 (0.9) 24 (0.8) 0.590 
Q waves 17 064 (5.1) 244 (5.5) 127 (4.9) 170 (5.7) 0.278 
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Table S6. Brier scores. 
Population 
Brier Score (95% CI) For 
Conventional Model 
Brier Score (95% CI) For 
ECG Abnormality Model 
Controls   
Cardiovascular disease 0.186 (0.182–0.190) 0.182 (0.178–0.187) 
No cardiovascular disease 0.053 (0.052–0.054) 0.052 (0.051–0.053) 
SMI   
Cardiovascular disease 0.223 (0.198–0.251) 0.222 (0.194–0.253) 
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Figure S1. Flowchart. 
  
449 584 patients in the CGPL in Denmark
between 2001 and 2015 yielding
a total of 978 901 ECGs
632 349 ECGs excluded in total:
Not most recent recording: 522 845
Controls with mental illness: 89 745
Age <16 years: 9026
Pacemaker rhythms: 6939
Not suitable for interpretation: 2918
Poor quality: 796
Missing data on age or sex: 60
Registration error (i.e. death date prior to ECG date): 20
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